Abstract Search

ea0070aep665 | Pituitary and Neuroendocrinology | ECE2020

Assessment of disease control in patients with acromegaly treated with long-acting somatostatin analogs (SMSa) varies according to the time when IGF-I levels are measured during the month following the injection

Cristina Albrici , Lecoq Anne-Lise , Vialon Magaly , Solange Grunenwald , Cocco Aldo , Hamdi Safouane , Vincenzo Cimino , Maione Luigi , Caron Philippe , Chanson Philippe

Introduction: Acromegaly is associated with multiple comorbidities and excess mortality. However, disease burden is reduced by maintaining IGF-1 (and/or GH) levels under safe levels. First generation long-acting SMSa, administered at monthly intervals, represent the first line medical treatment. According to guidelines, its efficacy is evaluated through IGF-I measurements. However, there are no data indicating the optimal time for measuring IGF-I levels after the SMSa injectio...

0 shares

Endocrine Abstracts

Assessment of disease control in patients with acromegaly treated with long-acting somatostatin analogs (SMSa) varies according to the time when IGF-I levels are measured during the month following the injection

BiosciAbstracts